Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ilaria, Avonto"'
Autor:
Claudia Giannotta, Barbara Castella, Ezio Tripoli, Daniele Grimaldi, Ilaria Avonto, Mattia D’Agostino, Alessandra Larocca, Joanna Kopecka, Mariella Grasso, Chiara Riganti, Massimo Massaia
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionBone marrow (BM) Vγ9Vδ2 T cells are intrinsically predisposed to sense the immune fitness of the tumor microenvironment (TME) in multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).MethodsIn this work, we
Externí odkaz:
https://doaj.org/article/2c1d4e5bf75f47d1859e683fe66f6ca6
Autor:
Patrizia Falco, Sara Bringhen, Ilaria Avonto, Francesca Gay, Fortunato Morabito, Mario Boccadoro, Antonio Palumbo
Publikováno v:
Expert Review of Anticancer Therapy. 7:945-957
Melphalan is an alkylating agent approved for the treatment of multiple myeloma and ovarian cancer. The combination of oral melphalan and prednisone was first introduced in the 1960s and remains the standard therapy for elderly multiple myeloma patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95a1fd3bf95104ec5e95fac82d8111bf
https://doi.org/10.1586/14737140.7.7.945
https://doi.org/10.1586/14737140.7.7.945
Autor:
Mario Boccadoro, Fortunato Morabito, Tommaso Caravita, Giulia Benevolo, Ilaria Avonto, Norbert Pescosta, Patrizia Falco, Federica Cavallo, Vincenzo Callea, Pellegrino Musto, Clotilde Cangialosi, Antonio Palumbo, Patrizia Pregno, Maria Teresa Ambrosini, Sara Bringhen
Publikováno v:
Blood. 109:2767-2772
In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival. In this multicenter phase 1/2 trial, dosing, safety, and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e51873f3f4c4ea97bcb8b435fa1b89
https://doi.org/10.1182/blood-2006-08-042275
https://doi.org/10.1182/blood-2006-08-042275
Publikováno v:
Expert Opinion on Investigational Drugs. 15:1565-1582
Multiple myeloma remains a fatal neoplasm and new treatments are urgently needed. In recent years, advances in understanding the molecular pathophysiology of myeloma and the mechanisms of drug resistance led to the development of several novel agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9614901a355a2618a89ce7acf287206
https://doi.org/10.1517/13543784.15.12.1565
https://doi.org/10.1517/13543784.15.12.1565
Autor:
Mario Boccadoro, Benedetto Bruno, Ilaria Avonto, Federica Cavallo, Patrizia Falco, Antonio Palumbo, Maria Teresa Ambrosini, Sara Bringhen
Publikováno v:
European Journal of Haematology. 76:273-277
Objectives: Thalidomide combined with conventional chemotherapies including oral melphalan shows significant anti-myeloma activity. To address this issue, feasibility and efficacy of a three drug combination consisting of intravenous (i.v.) melphalan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2773cb701d24389bae41a05ba247fdf3
https://doi.org/10.1111/j.1600-0609.2005.00610.x
https://doi.org/10.1111/j.1600-0609.2005.00610.x
Autor:
Riccardo, Balbo, Ilaria, Avonto, Dario, Marenchino, Laura, Maddalena, Giuseppe, Menardi, Gianmichele, Peano
Publikováno v:
Blood transfusion = Trasfusione del sangue. 8(4)
Autologous or allogenic platelet gel is a blood component that exploits the effects of the cytokines contained in platelet α granules to stimulate repair processes. The properties of platelet gel were first tested on chronic ulcers to accelerate hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6be5cbb9e0abb52873b33e214ed9b7b0
https://pubmed.ncbi.nlm.nih.gov/20967166
https://pubmed.ncbi.nlm.nih.gov/20967166
Autor:
Antonio Palumbo, Sara Bringhen, Patrizia Falco, Federica Cavallo, Maria Teresa Ambrosini, Ilaria Avonto, Francesca Gay, Tommaso Caravita, Benedetto Bruno, Mario Boccadoro
Publikováno v:
Cancer. 110(4)
BACKGROUND. Baseline parameters that may be predictive of outcome after thalidomide treatment have been investigated to identify which myeloma patient subgroups will most benefit from this drug. METHODS. Thalidomide has been used as a salvage regimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bbf2f48084adf8c63353ddfa117fdc0
https://pubmed.ncbi.nlm.nih.gov/17594696
https://pubmed.ncbi.nlm.nih.gov/17594696
Autor:
Pietro Leoni, Laura Corvatta, Antonio Palumbo, Massimo Offidani, Maria-Novella Piersantelli, Sara Bringhen, Patrizia Falco, Monica Marconi, Ilaria Avonto, Mario Boccadoro, Claudia Polloni
Publikováno v:
European journal of haematology. 78(4)
Objectives: Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy. Several salvage therapies have been explored, but the optimal combination regimen has not been defined. We performed a case-matched study c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd6e21d15a535ae383b13ed028d3bbe
https://pubmed.ncbi.nlm.nih.gov/17286608
https://pubmed.ncbi.nlm.nih.gov/17286608
Autor:
Patrizia Falco, Maria Teresa Petrucci, Fausto Rossini, Alessandra Larocca, Claudia Crippa, Paolo Corradini, Ilaria Avonto, Mario Boccadoro, Paola Omedè, Norbert Pescosta, Anna Marina Liberati, Francesca Patriarca, Renato Fanin, Antonio Palumbo, Nicola Giuliani, Massimo Offidani
Bortezomib has been evaluated as induction regimen to improve cyto-reduction before autologous stem cell transplant. Combinations including bortezomib, doxorubicin and dexamethasone have shown encouraging results. Melphalan at 100 mg/m2 has been sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c3423684dbe6b1803909cfd3d91c90
http://hdl.handle.net/2318/121845
http://hdl.handle.net/2318/121845
Autor:
Antonio Palumbo, Ilaria Avonto, Benedetto Bruno, Antonietta Falcone, Potito Rosario Scalzulli, Maria Teresa Ambrosini, Sara Bringhen, Francesca Gay, Cecilia Rus, Federica Cavallo, Patrizia Falco, Massimo Massaia, Pellegrino Musto, Mario Boccadoro
Publikováno v:
Clinical lymphomamyeloma. 6(6)
Background Bortezomib and thalidomide have shown synergy with melphalan and dexamethasone. We used this 4-drug combination as conditioning before autologous hematopoietic cell infusions. Patients and Methods Twenty-six patients with advanced-stage my
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05c6ba5b32d3fa3f6d4471230ef968b0
https://pubmed.ncbi.nlm.nih.gov/16796778
https://pubmed.ncbi.nlm.nih.gov/16796778